Charles Schwab Investment Management Inc Bio Xcel Therapeutics, Inc. Transaction History
Charles Schwab Investment Management Inc
- $519 Billion
- Q2 2024
A detailed history of Charles Schwab Investment Management Inc transactions in Bio Xcel Therapeutics, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 203,615 shares of BTAI stock, worth $138,458. This represents 0.0% of its overall portfolio holdings.
Number of Shares
203,615
Previous 190,970
6.62%
Holding current value
$138,458
Previous $538,000
51.67%
% of portfolio
0.0%
Previous 0.0%
Shares
20 transactions
Others Institutions Holding BTAI
# of Institutions
78Shares Held
7.26MCall Options Held
101KPut Options Held
205K-
Armistice Capital, LLC New York, NY2.99MShares$2.03 Million0.05% of portfolio
-
Vanguard Group Inc Valley Forge, PA970KShares$659,8920.0% of portfolio
-
Black Rock Inc. New York, NY441KShares$299,6650.0% of portfolio
-
Geode Capital Management, LLC Boston, MA267KShares$181,3680.0% of portfolio
-
Northern Trust Corp Chicago, IL195KShares$132,5680.0% of portfolio
About BioXcel Therapeutics, Inc.
- Ticker BTAI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 28,022,500
- Market Cap $19.1M
- Description
- BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and prop...